Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTEST: Phase 1-2 Master Protocol of Intravenous ATTR-01 in Select Epithelial Solid Tumours
2024-516722-59-00Phase 2Authorised
- Sponsor
- Accession Therapeutics
- Start
- Jan 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 2
01
Overview
Phase 2, single-arm trial of TROCEPT-X in Epithelial neoplasm and Nonhematologic neoplasms, sponsored by Accession Therapeutics. Primary endpoints: Incidence of adverse events and safety outcomes, Objective Response Rate (ORR) and 1 more. Planned start Jan 2026; status: authorised.
02
Drugs
TROCEPT-X
03
Conditions
Epithelial neoplasmNonhematologic neoplasms
Beyond the preview
Go deeper on 2024-516722-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516722-59-00.